Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Non-Current Liabilities (2020 - 2025)

Historic Total Non-Current Liabilities for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $294.0 million.

  • Foghorn Therapeutics' Total Non-Current Liabilities changed N/A to $294.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $294.0 million, marking a year-over-year change of. This contributed to the annual value of $329.5 million for FY2024, which is 925.24% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Total Non-Current Liabilities of $294.0 million as of Q3 2025.
  • Foghorn Therapeutics' 5-year Total Non-Current Liabilities high stood at $422.8 million for Q4 2021, and its period low was $104.9 million during Q3 2021.
  • In the last 5 years, Foghorn Therapeutics' Total Non-Current Liabilities had a median value of $379.9 million in 2023 and averaged $352.3 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 29036.09% in 2022, then tumbled by 1028.7% in 2023.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Total Non-Current Liabilities stood at $422.8 million in 2021, then fell by 4.26% to $404.7 million in 2022, then fell by 10.29% to $363.1 million in 2023, then decreased by 9.25% to $329.5 million in 2024, then fell by 10.79% to $294.0 million in 2025.
  • Its Total Non-Current Liabilities was $294.0 million in Q3 2025, compared to $302.1 million in Q2 2025 and $319.5 million in Q1 2025.